



PROJECT DOCUMENT



UNDAF Outcome(s)/Indicator(s):
(Link to UNDAF outcome. If no UNDAF, leave blank)

Expected Outcome(s)/Indicator (s):
(outcomes linked to the MYFF goal and service line)

Expected Output(s)/Indicator(s)
(CPAP outputs linked to the above CPAP outcome):

Implementing partner:
(designated institution/Executing agency)

Other Partners:

2.2 Survival and development rights of vulnerable groups are ensured within an environmentally sustainable framework
2.1 Carrying capacity of environment and (CPAP natural resources base is enhanced, MYFF Line 3.6 – National/ sectoral policy and planning to control emissions of ozone-depleting substances
Phase out of the Ozone Depleting Substances (ODS)

Department of Environment of the Ministry of Environment & Forests

Programme Period:	2006-2010
Programme Component:	Sustainable Environment & Energy Management
Project Title:	Phase-out of CFC consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh
Project ID:	00050306
Award ID:	00062091
Project Duration:	5 years
Management Arrangement:	National
Implementation Modality	

Total budget:	USD 2,776,788
Allocated resources:	
• Government	
• MP	USD 2,776,788
• In kind contributions	
Square Pharmaceuticals Ltd	USD 555,000
BEXIMCO Pharmaceuticals Ltd	USD 388,500
ACME Laboratories Ltd	USD 333,000

Narrative

The objective of this project is to phase-out the consumption of 76.3 ODP Tonnes of CFC 11 and CFC 12 used in the manufacture of Metered Dose Inhalers (MDIs) in Bangladesh by 2011. To be able to achieve this goal, the Multilateral Fund is providing assistance to the three local manufacturers of MDIs in Bangladesh to convert the production form using CFC to using HFA 134a. The assistance provided will comprise technical assistance and the provision of equipment.

Agreed by (Implementing Partner):

(Signature)
 A. H. M. Fiazul Kabir *hcc*
 Secretary
 Ministry of Environment and Forests
 Government of Bangladesh

Date 22.9.2008

Agreed by (Government):

(Signature)
 (Md. Mosharrif Hossain Bhuiyan, *ndc*)
 Additional Secretary
 Economic Relations Division
 Ministry of Finance
 People's Republic of Bangladesh

Date 07.10.08

Agreed by UNDP:

(Signature)

Date 07/10/2008

**Stefan Priesner
Country Director
UNDP-Bangladesh**

UNDP – MLF

&

Government of Bangladesh

In collaboration with

United Nations Development Programme

BGD/ARS/52/INV/26 – Phase-out of CFC consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh

The objective of this project is to phase-out the consumption of 76.3 ODP Tonnes of CFC 11 and CFC 12 used in the manufacture of Metered Dose Inhalers (MDIs) in Bangladesh by 2011. To be able to achieve this goal, the Multilateral Fund is providing assistance to the three local manufacturers of MDIs in Bangladesh to convert the production form using CFC to using HFA 134a. The assistance provided will comprise technical assistance and the provision of equipment.

The project will be executed by the Government of Bangladesh in collaboration with UNDP.

This project will be executed in parallel with the Transition Strategy for the phase out of CFC MDIs in Bangladesh. The Transition Strategy has been prepared by the Government of Bangladesh in collaboration with the United Nations Environment Programme and is separately funded and will be implemented by UNEP

The project will be implemented over a period of 5 years beginning in November 2007. The total budget of the project is US\$ 2,776,788 and will be funded by the MLF.

The grant requested to the MLF by the Government of Bangladesh is US\$ 2,776,788.

Starting Date – June 2008

Total Budget - US\$ 2,776,788

TABLE OF CONTENTS

UNDP PROJECT DOCUMENT BOOKMARK NOT DEFINED.	ERROR!
SECTION I: ELABORATION OF NARRATIVE	5
• PART I: Situation Analysis	5
• PART II: Strategy	7
• PART III: Management Arrangements	9
SECTION II: STRATEGIC RESULTS FRAMEWORK	11
• PART I: Monitoring and Evaluation Plan and Budget	11
SECTION III: TOTAL BUDGET AND WORKPLAN	14
• SIGNATURE PAGE Bookmark not defined.	Error!

ACRONYMS

DoE	Department of Environment
DPI	Dry Powder Inhaler
CFC	Chlorofluorocarbon
CPAP	UNDP Country Program Action Plan
HCFC	Hydrochlorofluorocarbon
HFC	Hydro fluorocarbon
HFA	Hydro fluoroalkane
IA	Implementing Agency
IOC	Incremental Operating Cost
MDI	Metered Dose Inhaler
MoEF	Ministry of Environment and Forests
MLF	Multilateral Fund
MPU	Montreal Protocol Unit
NOU	National Ozone Unit
ODP	Ozone Depleting Potential
ODS	Ozone Depleting Substances
TPMP	Terminal Phase-Out Management Plan
UNEP	United Nations Environment Programme
UNDP	United Nations Development Programme

SECTION I: ELABORATION OF NARRATIVE

PART I: Situation Analysis

Bangladesh ratified the Vienna Convention and Montreal Protocol in 1990. The status of ratification of Montreal Protocol and its amendments by Bangladesh is given in the table below.

Montreal Protocol	02.8.1990(Ac)
London Amendment	18.3.1994(R)
Copenhagen Amendment	27.11.2000(At)
Montreal Amendment	27.7.2001(At)
Beijing Amendment	Not ratified

Source: Ozone Secretariat

As one of the early entrants into this international agreement for Ozone Layer Protection, Bangladesh prepared a country programme, which sets-out the country's strategy and activities for phasing out consumption of Ozone Depleting Substances (ODSs) in the country in the year 1995. This document was subsequently updated in the year 2003.

The consumption of ODS in Bangladesh over the last five years is given in the table below.

Annex	Baseline	2002	2003	2004	2005
Annex A Gr I: CFC	582	328	333	295	263
Annex A Gr II: Halon	0	0	0	0	0
Annex B Gr I: Other CFCs	0	0	0	0	0
Annex B Gr II: CTC	5.7	14	7	6	0.8
Annex B Gr III: CH ₂ CCl ₂	0.9	1	0.9	0.6	0.5
Annex E: CH ₃ Br	0	0	0	0	0

Source: Article 7 data reports submitted to the Ozone Secretariat.

The country has complied with the phase out targets for Annex A Group I substances and Annex B Group II substances. Though Bangladesh's consumption of Annex B Group III substances were above the control limits in the year 2003 (i.e., 0.892 ODP tons of consumption against the consumption limits of 0.867 ODP tons), the country has implemented measures, which have reduced the consumption levels of Annex B Group III substances below the consumption limits. In the year 2005, the consumption of Annex B Group III substances is 0.5 ODP tons against the consumption limit of 0.61 ODP tons.

Consumption trends in Annex A Group I substances

In Bangladesh, CFCs – which are listed under Annex A Group I substances - are typically consumed in refrigeration and air-conditioning applications, foam applications and aerosol applications including MDIs. Bangladesh does not produce CFCs and is dependent on import


of CFCs from countries like India, China and developed countries producing CFCs for basic domestic needs of Article 5 countries. The supply of pharmaceutical grade CFC's for MDI manufacture will continue to be constrained in the coming years.

For phasing out ODS consumption in the country, which predominantly includes CFCs, Bangladesh signed a National Phase out Plan (NPP) agreement with the Executive Committee of the Multilateral Fund Secretariat (Decision 42/19). This agreement sets out phase out schedule for the ODS including CFCs. This project began implementation in March 2007 and will be revised in July 2007 to address the delay in the start of implementation.

The consumption trend of CFCs in Bangladesh compared to the Montreal Protocol control limits and the limits prescribed in the National Phase out Plan are given below.

	2004	2005	2006	2007	2008	2009	2010
Annex A Group I control limits (ODP tons)	580	290	290	87	87	87	0
Agreed limits as per NPP (ODP tons)	329	290	207	87	71	53	0
Actual consumption (ODP tons)	295	263					

Source: Appendix 2A of NPP agreement with the Executive Committee in 42nd Meeting of the Executive Committee. The shaded column presents the latest data reported to the Secretariat. This table does not include MDI consumption figures.



The Manufacture of CFC based MDI in Bangladesh poses a unique problem in terms of the country's compliance with the Montreal Protocol since the production was only first identified in 2004 during the preparation of the Country Programme Update and was not included in the country's National Phase Out Plan which seeks to phase out all consumption of CFC in Bangladesh. At its inception in 1997, the sector comprised two manufacturing plants, which consumed 11.379 ODP tons of CFC and has since grown to 76.3 ODP tons in 2006. This current level of consumption will place Bangladesh in non-compliance from 2007-2010 if the consumption is not addressed.

The Executive Committee acknowledged this situation and through its Decision 49/33 requested the Government of Bangladesh to submit to the 50th Meeting a proposal for the development of a transition strategy for the phase-out of CFC-based MDIs including facilitation for the earliest possible completion by the leading nationally-owned manufacturer of MDIs in Bangladesh of the manufacturing facilities for non-CFC MDIs currently under implementation. The Executive Committee subsequently decided to allow preparation of a Transition Strategy with the assistance of UNEP with an investment component with the assistance of UNDP (Decisions 50/19 and 5/20).

Industry structure for MDIs in Bangladesh

The demand for MDIs in Bangladesh is satisfied primarily by local manufacturing. There is importation of HFA Seretide in three strengths, 50, 125 and 250 at a total of 127, 846 units or 3.6% of all MDIs available in Bangladesh, there is also importation of 26, 427 multidose Seretide DPIs. The industry has grown from its inception in 1997 from an annual production of approximately 507,000 units to the current production of over 3,300,000 units per year which is approximately a 7 fold increase. It should be noted that the installed capacity of the three facilities is twice the produced capacity at approximately 6.3 million units, so that the full manufacturing capacity is not utilized currently and is in line with the expected future growth in demand in the local market as the drugs gain more widespread use. This increase in production has meant that the people of Bangladesh have recently gained access to affordable MDIs; however there is still a significant portion of the population without access to these drugs.

PART II: Strategy

Project objective

To Phase out the use of CFC in the manufacture of MDIs in Beximco Pharmaceuticals Ltd., The Acme Laboratories Ltd., and Square Pharmaceuticals Ltd.

This objective will be achieved through the provision of Technical Assistance and provision of Equipment to all three companies that manufacture CFC MDIs in Bangladesh as outlined below:

BEXIMCO

Equipment to be provided:

Equipment
SSP (X1/005/H08) Lobe Pump
Vacuum Pump P14019/004
Suspension Vessel with stirrer (100 liters)
Microdoser product filler P2001/021

Product Development and Technical Assistance to be provided:

Formulations that will be developed by a Laboratory and transferred to Beximco:

- Salmeterol Xinafoate + Fluticasone Propionate (50, 125 and 250)
- Ipratropium Bromide

Formulations that Technical Assistance only will be provided:

- Ciclesonide (80, 160)
- Salbutamol + Ipratropium Bromide

Formulations that partial retroactive payment will be made

- Salbutamol
- Beclomethasone Dipropionate (100, 250)

Incremental Operating Costs to be provided:

- Retroactive IOCs will be paid for Salbutamol and Beclomethasone
- IOC will be paid for Salmeterol + Fluticasone once the product is launched by Beximco.

SQUARE

Equipment to be provided:

Equipment
Retrofitting of current low pressure vessel
Documents, installation, travel
Heavy Duty Mixer (Silverstone Machines UK)
Microdoser product filler P2001/021
Pamasol Diaphragm Filler P2079 plus autoguard
Pamasol Diaphragm Pump P2089
Propellant pump and flexible piping (Pamasol)
Purger plus autoguard
SS filter housing and cartridge (Pall India Pvt)
SSP (X1/005/H08) Lobe Pump
Suspension Vessel with stirrer (150 liters)
Vacuum Pump P14019/004

Product Development and Technical Assistance to be provided:

Formulations that will be developed by a Laboratory and transferred to Square:

- Salbutamol
- Salmeterol Xinafoate + Fluticasone Propionate (50, 125 and 250)
- Ipratropium Bromide

Formulations that Technical Assistance only will be provided:

- Ciclesonide (80, 160)
- Beclomethasone Dipropionate (100, 250)
- Salbutamol + Ipratropium Bromide

Incremental Operating Costs to be provided:

- IOC will be paid for Salbutamol, Salmeterol + Fluticasone, Beclomethasone, Ipratropium Bromide and Ciclesonide once the products are launched by Square.

ACME

Equipment to be provided:

Equipment
Retrofitting of current low pressure vessel
Documents, installation, travel
Heavy Duty Mixer (Silverstone Machines UK)
Microdoser product filler P2001/021
Pamasol Diaphragm Filler P2079 plus autoguard
Pamasol Diaphragm Pump P2089
Propellant pump and flexible piping (Pamasol)
Purger plus autoguard
SS filter housing and cartridge (Pall India Pvt)
SSP (X1/005/H08) Lobe Pump
Suspension Vessel with stirrer (100 liters)
Vacuum Pump P14019/004

Product Development and Technical Assistance to be provided:

Formulations that will be developed by a Laboratory and transferred to ACME:

- Salbutamol
- Salmeterol Xinafoate + Fluticasone Propionate (50, 125 and 250)
- Beclomethasone Dipropionate (100, 250)

Incremental Operating Costs to be provided:

- IOC will be paid for Salmeterol and Beclomethasone once the products are launched by ACME

Project assumptions:

- Stability tests are going to be undertaken jointly with support by the companies in the three cases.
- A minimum of 6 months accelerated time stability data will be required to achieve product registration and these can be done within the manufacturing companies.
- No clinical data are required to register the HFA MDIs.

PART III: Management Arrangements

This Project will be executed under the National Implementation Modality and will be implemented by the National Ozone Unit of Bangladesh which falls under the purview of the Department of Environment, Ministry of Environment and Forests.

To assist the Government of Bangladesh manage this project, an international expert will be hired to carry out the following tasks:

- Develop TORs for Technical Assistance and Equipment
- Conduct Technical evaluation of all bids for Technical Assistance and Equipment

- Act as Liaison between Technology and Equipment supplier and the Government of Bangladesh/UNDP
- Verify project deliverables are met
- Preparation of Project Completion Report
- Any other task as required by the Government of Bangladesh/UNDP

The Government of Bangladesh as executing agency will be required to provide the following services:

These services include, but are not limited to the following:

- Preparation of all TORs for consultants hired under this project
- All tendering and hiring of goods and services
- All annual progress reports
- Ensuring all targets are met

UNDP as implementing agency will be responsible for:

- Ensuring performance and financial verification in accordance with specific UNDP and Multilateral Fund procedures, rules and regulations;
- Providing verification to the Executive Committee that the consumption targets and the activities as stated in this project document have been met as per schedule;
- Assisting the Government of Bangladesh in preparation of yearly implementation progress reports;
- Ensuring that technical reviews undertaken by UNDP are carried out by appropriate independent technical experts, including the designation of an independent expert when required to verify that payment milestones have been achieved;
- Carrying out required supervision missions to monitor the delivery of the services included in this Project Document to the designated beneficiary;
- Ensuring the presence of an operating mechanism to allow effective, transparent implementation of the project, and accurate data reporting;
- Ensuring that disbursements/compensation payments are made to Government, technology supplier and equipment and material suppliers on agreed terms upon receipt of invoices which are properly substantiated;
- Providing assistance with policy when required;
- Providing independent technical supervision missions and certifies completion of the project;
- Through a Handover Protocol, HOP (Annex 9 of this project document), transferring the ownership of the equipment purchased under this project to the beneficiary laboratory once the project is completed and ensuring that the conditions listed in the "Certificate of Completion" (Annex 10 of this Project Document) are accomplished;

- Providing a copy of the following relevant documentation to the Government of Bangladesh and the technology provider:
 - Project Document, letter confirming UNDP role as paying agent,
 - Handover Protocol (HOP) and
 - Certificate of Completion (COC)

SECTION II: STRATEGIC RESULTS FRAMEWORK

PART I: Monitoring and Evaluation Plan and Budget (Dates should be effective from the day of GoB approval and NPD in place)

Main outcome	Main Activity	Sub Activities	
Procurement Component	Selection of technical consultant	Preparation of ToRs	
		Consultant on board	
	Equipment Procurement for two stage filling	Place order for two stage filling equipments	
		Commissioning and hand over Square two stage	
	Installation and Commissioning	Commissioning and hand over ACME two stage	
		Equipment Procurement for single stage filling	Place order for single stage filing equipments
	Installation and Commissioning	Commissioning and hand over Beximco single stage	
Commissioning and hand over Square single stage			
Commissioning and hand over ACME single stage			
Procurement of formulations and Technical Assistance	Finalization of specifications		
	Contract Awarded to provider		
Delivery of Technical Assistance	Salbutamol Formulation	Preparation of Formulation	
		Selection of lead candidate	
		Transfer of Product to Square	
		Batches Released	
		6 months data available	
		12 months test available	
		Submit application	
		Product Launch	
		Transfer of Product to ACME	
		Batches released	
	6 months data available		
	12 months data available		
	Submit application		
	Product Launch		
	Beclomethasone Formulation	Preparation of Formulation	
		Selection of lead candidate (Beclomethasone Formulation)	
		Transfer of Product to Square	
Batches Released			
6 months data available			
12 months data available			
Submit application			
Product Launch			

Main outcome	Main Activity	Sub Activities	
		Transfer of Product to ACME	
		Batches Released	
		6 months data available	
		12 months data available	
		Submit application	
		Product Launch	
	Ciclesonide Formulation	Beximco	
		Product Development with Technical Assistance	
		Selection of lead candidate (Ciclesonide Formulation)	
		Batches Released	
		6 months data available	
		12 months data available	
		Submit application	
		Product Launch	
		Square	
		Product Development with Technical Assistance	
		Selection of lead candidate (Ciclesonide Formulation)	
		Batches Released	
		6 months data available	
		12 months data available	
	Submit application		
	Product Launch		
	Salmeterol + Fluticasone Formulation	Preparation of Formulation	
		Product Development at service provider	
		Selection of lead candidate	
		Transfer of Product to Beximco	
		Batches Released for	
		6 months data available	
		12 months test available	
		Submit application	
Product Launch			
Transfer of Product to Square			
Batches Released			
6 months data available			
12 months data available			
Submit application			
Product Launch			

Main outcome	Main Activity	Sub Activities	
		Transfer of Product to ACME	
		Batches Released for	
		6 months data available	
		12 months data available	
		Submit application	
		Product Launch	
	Ipratropium Formulation	Preparation of Formulation	
		Product Development at service provider	
		Selection of lead candidate	
		Transfer of Product to Beximco	
		Batches Released	
		6 months data available	
		12 months test available	
		Submit application	
		Product Launch	
		Transfer of Product to Square	
		Batches Released	
		6 months data available	
		12 months data available	
		Submit application	
	Product Launch		
	Salbutamol + Ipratropium Formulation	Beximco	
		Product Development with Technical Assistance	
		Selection of lead candidate	
		Batches Released	
		6 months data available	
		12 months test available	
		Submit application	
		Product Launch	
		Square	
Product Development with Technical Assistance			
Selection of lead candidate (Salbutamol + Ipratropium Formulation)			
Batches Released			
1 month data available			
3 months data available			
6 months data available			
12 months data available			
Submit application			
Product Launch			
Project Closure	project Closure	Project operationally closed	
		Project financially closed	
		Submit PCR to MLFS	
		End	

The financing Plan and Project Implementation are presented in Pages 33 of the attached Proposal Document.

A summary of the technical project costs is provided below:

Project Phase	Projected Costs (\$)
Equipment Replacement and Installation	\$ 946, 306
Product Development and Overall Supervision (including retroactive portion of Beximco)	\$ 1, 422, 394
Incremental Operating Costs	\$ 309, 914
Contingency @ 10% of ICC	\$ 98, 174
Total	\$ 2,776, 788

Project Time table

The project timeline is attached to the present document.

SECTION III: TOTAL BUDGET AND WORKPLAN

Country: Bangladesh
 Business Unit: BGD10
 Short Title: BGD/PHA/52/INV/26
 Long Title: Phase-out of CFC consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh
 Total Budget: US\$ 2,776,788

Outcome/Atlas Activity	Responsible Party/ Implementing Agent	Fund ID	Donor Name	Atlas Budgetary Account Code	ATLAS Budget Description	Amount t 2008 (USD)	Amount t 2009 (USD)	Amount t 2010 (USD)	Amount t 1011 (USD)	Amount t 1012 (USD)	Amount t 1013 (USD)	Total (USD)	See Budget Notes
Activity 1 Technical Assistance for Overall Project Implementation	UNDP Bangladesh in collaboration with UNDP/MPU	63030	10009	71200	International Consultant-1 (36 mm)	10,000	27,600	27,600	17,600	-	-	82,800	TOR provided
Activity 2 Local Support	DoE under Ministry of Environment and Forests	63030	10009	71300	Local Consultant -1 (36 mm)	1,000	4,000	4,000	3,000	-	-	12,000	TOR provided
Activity 3 Product Development, including Technical Assistance and Procurement of Services	UNDP Bangladesh in collaboration with UNDP/MPU	63030	10009	72100	Product Development	119,044	237,916	-	494,792	323,541	152,291	1,327,584	TOR provided
Activity 4 Equipment for Conversion of Production Lines at Beximco, Square and Acme	UNDP Bangladesh in collaboration with UNDP/MPU	63030	10009	72200	Equipment	-	189,261	757,045	-	-	-	946,306	
Activity 5 Payment for Incremental Operating Costs incurred as a result of producing the new drugs	UNDP Bangladesh in collaboration with UNDP/MPU	63030	10009	72600	IOC	-	212,250	-	87,104	10,560	-	309,914	
Activity 6 Contingency Costs for	UNDP Bangladesh in collaboration	63030	10009	74500	Miscellaneous	-	20,000	48,174	30,000	-	-	98,174	

Outcome/Atlas Activity	Responsible Party/Implementing Agent	Fund ID	Donor Name	Atlas Budgetary Account Code	ATLAS Budget Description	Amount t 2008 (USD)	Amount t 2009 (USD)	Amount t 2010 (USD)	Amount t 1011 (USD)	Amount t 1012 (USD)	Amount t 1013 (USD)	Total (USD)	See Budget Notes
the Equipment Component	with UNDP/MPU												
Grand total					sub-total	130,044	691,027	836,819	632,496	334,101	152,291	2,776,788	
												USD 2,776,788	

Budget Notes:

1. Product Development – 20% of Total Budget minus retroactive payment to Beximco (\$ 119, 054 – will be paid once Beximco signs enterprise agreement) will be paid on signature with Service Provider and then payment will be phased to pay on last launch date of each of the six products.
2. Equipment – 20% will be paid on signature of contract with service provider, 30% on Delivery to Bangladesh and 50% at hand over to each company
3. IOC – retroactive payment to Beximco for Salbutamol and Beclomethasone on signature of Beximco. Remainder to be paid to each company on launch of the products.
4. IOC can not be extended to any additional drugs

ANNUAL WORK PLAN FOR 2008

EXPECTED OUTPUT	PLANNED ACTIVITIES/ATLAS	TIMEFRAME				RESPONSIBLE PARTY	PLANNED BUDGET			
		Q1	Q2	Q3	Q4		Source of Funds	Account	Budget Description	Amount US\$
Procurement of Goods and Services	1. Procurement of Services - International Consultant (TOR Required)			5,000	5,000	UNDP Bangladesh in collaboration with UNDP/MPU	10009	71200	International consultant	10,000
	2. Local Consultant				1,000	DoE under MoEF	10009	71300	Local Consultant	1,000
	2. Procurement of Service - Product Development				119,044	UNDP Bangladesh in collaboration with UNDP/MPU	10009	72100	Contractual Services - Companies	119,054
	3. Procurement of Equipment					DoE under MoEF	10009	72200	Equipment & Furniture	-
	4. Miscellaneous					DoE under MoEF	10009	74500	Miscellaneous	-
	5. IOC					UNDP Bangladesh in collaboration with UNDP/MPU	10009	72600	IOC	-
	Sub-total				5,000					
	Grand Total				125,044					\$ 130,044

ANNUAL WORK PLAN FOR 2009

EXPECTED OUTPUT	PLANNED ACTIVITIES/ATLAS	TIMEFRAME				RESPONSIBLE PARTY	PLANNED BUDGET			
		Q1	Q2	Q3	Q4		Source of Funds	Account	Budget Description	Amount US\$
Procurement of Goods and Services	1. Procurement of Services - International Consultant (TOR Required)	6,900	6,900	6,900	6,900	UNDP Bangladesh in collaboration with UNDP/MPU	10009	71200	International consultant	27,600
	2. Local Consultant	1,000	1,000	1,000	1,000	DoE	10009	71300	Local Consultant	4,000
	2. Procurement of Service - Product Development					UNDP Bangladesh in collaboration with UNDP/MPU	10009	72100	Contractual Services - Companies	-
	3. Procurement of Equipment		757,045			UNDP Bangladesh in collaboration with UNDP/MPU	10009	72200	Equipment & Furniture	757,045
	4. Miscellaneous	10,000	20,000	10,000	8,174	DoE under MoEF	10009	74500	Miscellaneous	48,174
	5. IOC				UNDP	10009		IOC	-	
	Sub-total	17,900	784,945	17,900	16,074					
	Grand Total									\$ 836,819

ANNUAL WORK PLAN FOR 2010

EXPECTED OUTPUT	PLANNED ACTIVITIES/ATLAS	TIMEFRAME				RESPONSIBLE PARTY	Source of Funds	Account	Budget Description	Amount US\$
		Q1	Q2	Q3	Q4					
		PLANNED BUDGET								
Procurement of Goods and Services	1. Procurement of Services - International Consultant (TOR Required)	6,900	6,900	6,900	6,900	UNDP Bangladesh in collaboration with UNDP/MPU	10009	71200	International consultant	27,600
	2. Local Consultant	1,000	1,000	1,000	1,000	DoE under MoEF	10009	71300	Local Consultant	4,000
	2. Procurement of Service - Product Development			237,916		UNDP Bangladesh in collaboration with UNDP/MPU	10009	72100	Contractual Services - Companies	237,916
	3. Procurement of Equipment		189,250			UNDP Bangladesh in collaboration with UNDP/MPU	10009	72200	Equipment & Furniture	189,261
	4. Miscellaneous	5,000	5,000	5,000	5,000	DoE under MoEF	10009	74500	Miscellaneous	20,000
	5. IOC	212,250				UNDP Bangladesh in collaboration with UNDP/MPU	10009		IOC	212,250
	Sub-total	225,150	202,161	250,816	12,900					
	Grand Total									\$ 691,027

ANNUAL WORK PLAN FOR 2011

	Q1	Q2	Q3	Q4	Source of Funds	Account	Budget Description	Amount US\$
Procurement of Goods and Services	1. Procurement of Services - International Consultant (TOR Required)	6,900	3,800		UNDP Bangladesh in collaboration with UNDP/MPU	71200	International consultant	17,600
	2. Local Consultant	1,000	1,000		DoE under MoEF	71300	Local Consultant	3,000
	2. Procurement of Service - Product Development	164,930.67	164,930.67	164,930.67	UNDP Bangladesh in collaboration with UNDP/MPU	72100	Contractual Services - Companies	494,792
	3. Procurement of Equipment				UNDP Bangladesh in collaboration with UNDP/MPU	72200	Equipment & Furniture	
	4. Miscellaneous	7,500	7,500	7,500	DoE under MoEF	74500	Miscellaneous	30,000
5. IOC	87,104		29,034.67	DoE under MoEF	10009	IOC	87,104	
Sub-total	15,400	209,365.33	206,265.33	201,465.33				
Grand Total								\$ 632,496

ANNUAL WORK PLAN FOR 2012

EXPECTED OUTPUT	PLANNED ACTIVITIES/ATLAS	TIMEFRAME				RESPONSIBLE PARTY	Source of Funds	Account	PLANNED BUDGET	
		Q1	Q2	Q3	Q4				Budget Description	Amount US\$
Procurement of Goods and Services	1. Procurement of Services - International Consultant (TOR Required)					UNDP Bangladesh in collaboration with UNDP/MPU	10009	71200	International consultant	-
	2. Local Consultant					DoE	10009	71300	Local Consultant	-
	2. Procurement of Service - Product Development			161,770.50	161,770.50	UNDP Bangladesh in collaboration with UNDP/MPU	10009	72100	Contractual Services - Companies	323,541
	3. Procurement of Equipment					UNDP Bangladesh in collaboration with UNDP/MPU	10009	72200	Equipment & Furniture	-
	4. Miscellaneous					DoE under MoEF	10009	74500	Miscellaneous	-
5. IOC			5,280	5,280	DoE under MoEF	10009		IOC	10,560	
	Sub-total			167,050.50	167,050.50					
	Grand Total									\$ 334,101

ANNUAL WORK PLAN FOR 2012

COMPANYWISE COST BREAK UP

(In US\$)

Company Name	Equipment	Contingency Cost for Equipment	Product Development	Incremental Operating Cost	US \$
Beximco	186354	19338	404059	220279	830,029
Square	392676	40735	577206	76794	1,087,412
Acme	367294	38103	346323	12838	764,559
Total	946324	98176	1327588	309912	2,682,000

Note : Cost for local and international consultant not included in the above budget.

Annex : Risk Log

Risk No.	Risk Description	Impact	Probability	Degree of Impact	Mitigation	Notes
1 Political	Involvement of civil service officials in Election 2008 for electoral administration and management. Political instability.	It may cause delay in project implementation.	M	M	The timeframe of AWP will be designed considering the impact of Election 2008.	
2 Operational	<p>Delay in identifying the office space, recruitment and procurement. Timely availability of fund. Cooperation and understanding between the pharmaceutical industries and the project management on implementation modalities.</p> <p>Decline of the US dollar versus the Euro resulting in increased costs of equipment and services from the European Market</p> <p>No supply of CFC post 2009</p>	<p>Delay in project commencement</p> <p>Reduced funding available for procurement of equipment and services, which will delay project since additional funds may be needed to complete the activities</p> <p>This can result in closure of the CFC lines which would could cause a diminished supply of locally produced until the drugs can be manufactured in HFA. This can cause a market distortion since companies already producing HFA can fill the market. The impact however does not impact the objectives of the project</p>	<p>M</p> <p>H</p> <p>M</p>	<p>L</p> <p>H</p> <p>L</p>	<p>The existing project office will be used. HR and procurement plan will be submitted in the beginning of the year</p> <p>The equipment and services should be identified and funds committed as soon as possible</p> <p>Ensure that the Transition Strategy being implemented by UNEP considers this issue and makes contingency plans to address this issue should it occur.</p>	<p>Depends on the signature of the project document</p>

<p>3 Environmental</p>	<p>Natural disaster like flood, cyclone.</p>	<p>Sudden cancellation of programme activities and less resource delivery.</p>	<p>H</p>	<p>M</p>	<p>Alternatives will be identified and approved by concerned authority</p>	
<p><i>Low- (L) Medium-(M) High- (H)</i></p>						

United Nations Development Programme
Phase out of CFC Consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh
BGD/05/G06
Budget-A



ATLAS Account	Description	ACTIVITY	Fund	Donor	Implementing Partner	Total	2008	2009	2010	2011	2012	2013
International Consultant												
71200	Short Term International Consultant	ACTIVITY1	63030	10009	UNDP/IMP	Net Amount 82,800	10,000	27,600	27,600	17,600		
						Line total 82,800	10,000	27,600	27,600	17,600		
National Consultants												
71300	National Consultant	ACTIVITY2	63030	10009	DoE	Net Amount 12,000	1,000	4,000	4,000	3,000		
						Line total 12,000	1,000	4,000	4,000	3,000		
Subcontracts												
72100	Subcontract for Product Development	ACTIVITY3	63030	10009	UNDP/IMP	Net Amount 1,327,594	119,054		237,916	494,792	323,541	152,291
						Line total 1,327,594	119,054		237,916	494,792	323,541	152,291
Equipment												
72200	Equipment for Conversion	ACTIVITY4	63030	10009	UNDP/IMP	Net Amount 946,306		757,045	189,261			
						Line total 946,306		757,045	189,261			
Micro Capital Grant												
72600	Incremental Operating Costs	ACTIVITY5	63030	10009	UNDP/IMP	Net Amount 309,914			212,250	87,104	10,560	
						Line total 309,914			212,250	87,104	10,560	
Miscellaneous												
74500	Sundries (Miscellaneous)	ACTIVITY6	63030	10009	UNDP/IMP	Net Amount 98,174		48,174	20,000	30,000		
						Line total 98,174		48,174	20,000	30,000		
	BUDGET TOTAL					Net Amount 2,776,788	130,054	836,819	691,027	632,496	334,101	152,291



SQUARE PHARMACEUTICALS LTD.

CORPORATE HEADQUARTERS

SQUARE CENTRE

48, Mohakhali Commercial Area, Dhaka-1212, Bangladesh
Tel : (880-2) 8833047-56, 8859007 (10 Lines), Fax : 8828768
E-mail : info@squaregroup.com. Web : http://www.squarepharma.com.bd



Date 27.11.2007

To: The Executive Committee
Of the Multilateral Fund for the Implementation
of the Montreal Protocol, United Nations


c/o Maria Nolan,
Chief Officer, Multilateral Fund Secretariat
1800 McGill College Avenue, 27th Floor,
Montreal, Quebec, Canada
H3A 3J6

Re: Conversion of CFC-MDI manufacturer facilitates on Bangladesh to HFA

This letter represents a commitment by Square Pharmaceuticals Ltd. to provide stability testing, laboratory analysis and overheads as a contribution to the project "Phase-out of CFC consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh" that was approved by the Executive Committee at its 52nd meeting. It is estimated that the value of this in kind contribution is US \$ 555,000.00

Square Pharmaceuticals Ltd. also commits to stop production of CFC-MDI products converted to non-CFC technology immediately upon completion of the conversion project.

Sincerely,



Muhammadul Haque
Director, Marketing

Signature and stamp

Square Pharmaceuticals Ltd.
48, Mohakhali Commercial Area,
Dhaka-1212, Bangladesh

MUHAMMADUL HAQUE
Director, Marketing
Square Pharmaceuticals Ltd.

CC: Mr. Mohammad Reazuddin, Director (Technical), and National Project Director All ODS Projects, Department of Environment, Government of the People's Republic of Bangladesh

Dr. Suely Carvalho, Chief, Montreal Protocol Unit, and Principal Technical Advisor
Chemicals

Mr. Anil Sookdeo, Programme Specialist, Montreal Protocol Unit

BEXIMCO PHARMACEUTICALS LTD.

MEMBER OF THE BEXIMCO GROUP

17 Dhanmondi R/A, Road No. 2, Dhaka-1205, Bangladesh
Phones : +880-2-8619151-5, 8619091-5, Fax : +880-2-8613888 Telex : 675848 BXM B]
Website : www.beximco-pharma.com

November 28, 2007

To: The Executive Committee
Of the Multilateral Fund for the
Implementation of the Montreal
Protocol

C/O Maria Nolan,
Chief Officer, Multilateral Fund
Secretariat
1800 McGill College Avenue, 27th Floor,
Montreal, Quebec, Canada
H3A 3J6

Re: Conversion of CFC-MDI manufacturer facilities on Bangladesh to HFA

This letter represents a commitment by Beximco Pharmaceuticals Ltd. to provide stability testing, laboratory analysis and overheads as a contribution to the project "Phase-out of CFC consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh" that was approved by the Executive Committee at its 52nd meeting. It is estimated that the value of this in kind contribution is US \$388,500.00

Beximco Pharmaceuticals Ltd. also commits to stop production of CFC-MDI products converted to non-CFC technology immediately upon completion of the conversion project.

Yours sincerely,

BEXIMCO PHARMACEUTICALS LTD.

Rabbur Reza
Rabbur Reza
Director, Marketing

CC: Mr. Mohammad Reazuddin, Director (Technical), and National Project Director All ODS Projects, Department of Environment, Government of the People's Republic of Bangladesh

Dr. Suely Carvalho, Chief, Montreal Protocol Unit, and Principal Technical Advisor - Chemicals

Mr. Anil Sookdeo, Programme Specialist, Montreal Protocol Unit



Manufacturer of Quality Medicines



National Export Trophy
GOLD 1994-1995



National Export Trophy
GOLD 1998-1999



National Export Trophy
GOLD 1998-2000



The ACME Laboratories Ltd.
MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001:2000, ANSI/ASQC Q9001:2000

CERTIFIED COMPANY

www.acmeglobal.com

Date: November 26, 2007

To: The Executive Committee
Of the Multilateral Fund for the
Implementation of the Montreal Protocol,
United Nations


C/o Maria Nolan,
Chief Officer, Multilateral Fund Secretariat
1800 McGill College Avenue, 27th Floor,
Montreal, Quebec, Canada
H3A 3J6

Re: Conversion of CFC-MDI manufacturer facilitates on Bangladesh to HFA

This letter represents a commitment by The ACME Laboratories Ltd. to provide stability testing, laboratory analysis and overheads as a contribution to the project "Phase-out of CFC consumption in the Manufacture of Metered Dose Inhalers (MDIs) in Bangladesh" that was approved by the Executive Committee at its 52nd meeting. It is estimated that the value of this in kind contribution is US \$333,000.00

ACME Laboratories Ltd. also commits to stop production of CFC-MDI products converted to non-CFC technology immediately upon completion of the conversion project.

Sincerely,


Md. Rafiqul Islam
Director, Sales & Marketing
The ACME Laboratories Ltd.
1/4 Kallayanpur, Mirpur Road,
Dhaka-1207
Bangladesh



Stamp

CC: Mr. Mohammad Reazuddin, Director (Technical), and National Project Director All ODS Projects, Department of Environment, Government of the People's Republic of Bangladesh

Dr. Suely Carvalho, Chief, Montreal Protocol Unit, and Principal Technical Advisor
Chemicals

Mr. Anil Sookdeo, Programme Specialist, Montreal Protocol Unit

Corporate Office:

Court de la ACME
1/4, Kallayanpur, Mirpur Road
Dhaka-1207, Bangladesh.
Phone : 88-02-9004194-6
Fax : 88-02-8054798

Plant:

Dhamrai, Dhaka, Bangladesh.
Phone : 88-02-9352901-02
06222-88935, 88042, 88047
Fax : 88-02-9340146
E-mail : acmefact@bangla.net

